Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

NORETHINDRONE ACETATE/ETHINYL ESTRADIOL & ETHINYL ESTRADIOL

All products: not a benefit

Other products in the same Health Canada class (G03A) — coverage varies; not interchangeable

  • Etonogestrel (Nexplanon): general benefit

Lolo · DIN 02417456 · 1mg/10mcg & 10mcg · tablet-28 tablet Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Lolo (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Lolo · DIN 02417456 Manufacturer: AbbVie Corporation; listing date 2026-06-30 Health Canada: Marketed since 2024-05-06 · brand LOLO · ATC G03AB04 NORETHISTERONE AND ESTROGEN · form Tablet · route Oral · ingredients NORETHINDRONE ACETATE 1 MG, ETHINYL ESTRADIOL 10 MCG, ETHINYL ESTRADIOL 10 MCG · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Lolo: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90215 · Verify on the e-Formulary ↗ (DIN 02417456)

Source record
DIN 02417456: Lolo Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 681200006; group id 730; item number 1794; lccId None; manufacturer id ABV Source form: Tab-28 Tab Pk; strength: 1mg/10mcg & 10mcg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02417456 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90215
Interchangeable products
Elfy · DIN 02553481 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (68:12 Contraceptives) and how they are covered

Matched class: 68:12 Contraceptives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ETONOGESTREL, LEVONORGESTREL 68:12 Contraceptives

ETONOGESTREL

· 1 products · General benefit · strengths: 68mg/Implant · ER Subdermal Implant

LEVONORGESTREL

· 2 products · General benefit · strengths: 19.5mg, 52mg · Insert

ETHINYL ESTRADIOL & ETONOGESTREL

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.120mg & 0.015mg/24 hr · Slow Release Vag Ring Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:12
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:28 Pituitary Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: pregnancy
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ETHINYL ESTRADIOL & NORETHINDRONE ETHINYL ESTRADIOL & NORETHINDRONE · General benefit Indications BREVICON 0.5/35 and BREVICON 1/35 (norethindrone and ethinyl estradiol) are indicated for: • the prevention of pregnancy. 1.1. PM: https://pdf.hres.ca/dpd_pm/00081309.PDF; date 2025-08-07; DIN 02187086; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS LOLO® (ethinyl estradiol / norethindrone acetate and ethinyl estradiol) is indicated for: • the prevention of pregnancy. In a one year (thirteen 28-day cycles) multicenter open-label clinical trial 1,582 women were studied to assess the safety and efficacy of LOLO. In this study 1,270 women 18 to 35 years of age were studied to assess the efficacy of LOLO, completing the equivalent of 12,482 28-day evaluable cycles of exposure. The pregnancy rate (Pearl Index [PI]) in women 18 to 35 years of age was 2.92 pregnancies per 100 women-years of use. See 14 CLINICAL TRIALS. The efficacy of LOLO in women with a body mass index > 35 kg/m2 has not been evaluated. Exposure to exogenous estrogen with LOLO is less than with other combined oral contraceptives with similar synthetic estrogens. Any benefits from the lower estrogen exposure provided by LOLO have not been evaluated. 1.1 Pediatrics Pediatrics (< 18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics: No data are available to Health Canada; therefore, Health Canada has not authorized an indication for… https://pdf.hres.ca/dpd_pm/00077458.PDF PM date: DEC 12, 2013 Source product: LOLO; DIN 02417456; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Lolo: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026